Amgen Inc (AMGN)vsTotalEnergies SE ADR (TTE)
AMGN
Amgen Inc
$349.58
-1.19%
HEALTHCARE · Cap: $189.18B
TTE
TotalEnergies SE ADR
$89.40
+0.78%
ENERGY · Cap: $195.51B
Smart Verdict
WallStSmart Research — data-driven comparison
TotalEnergies SE ADR generates 394% more annual revenue ($183.96B vs $37.22B). AMGN leads profitability with a 21.0% profit margin vs 8.2%. TTE appears more attractively valued with a PEG of 0.72. TTE earns a higher WallStSmart Score of 72/100 (B).
AMGN
Buy62
out of 100
Grade: C+
TTE
Strong Buy72
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-21.5%
Fair Value
$277.86
Current Price
$349.58
$71.72 premium
Intrinsic value data unavailable for TTE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 85 in profit
Strong operational efficiency at 33.8%
Large-cap with strong market position
Keeps 21 of every $100 in revenue as profit
Generating 1.5B in free cash flow
Earnings expanding 57.1% YoY
Large-cap with strong market position
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 20.3%
Areas to Watch
Expensive relative to growth rate
4.4% earnings growth
Trading at 20.5x book value
Distress zone — elevated risk
3.4% revenue growth
Grey zone — moderate risk
Weak financial health signals
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AMGN
The strongest argument for AMGN centers on Return on Equity, Operating Margin, Market Cap. Profitability is solid with margins at 21.0% and operating margin at 33.8%.
Bull Case : TTE
The strongest argument for TTE centers on EPS Growth, Market Cap, PEG Ratio. PEG of 0.72 suggests the stock is reasonably priced for its growth.
Bear Case : AMGN
The primary concerns for AMGN are PEG Ratio, EPS Growth, Price/Book. Debt-to-equity of 6.24 is elevated, increasing financial risk.
Bear Case : TTE
The primary concerns for TTE are Revenue Growth, Altman Z-Score, Piotroski F-Score.
Key Dynamics to Monitor
AMGN profiles as a mature stock while TTE is a value play — different risk/reward profiles.
AMGN carries more volatility with a beta of 0.42 — expect wider price swings.
AMGN is growing revenue faster at 5.8% — sustainability is the question.
AMGN generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
TTE scores higher overall (72/100 vs 62/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amgen Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
Visit Website →TotalEnergies SE ADR
ENERGY · OIL & GAS INTEGRATED · USA
TotalEnergies SE is a global integrated oil and gas company. The company is headquartered in Paris, France.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?